FDA Clearance Tracker · P050051-S050
ARCHITECT AUSAB
Last checked: Nov 20, 2026Latest source record: Jan 19, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jan 19, 2024
Approved
Time to decision
263 days
Received May 1, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class II
The decision
- FDA number
- P050051-S050
- Device name
- ARCHITECT AUSAB
- Applicant
- Abbott Laboratories, Inc.
- Applicant location
- Abbott Park, IL
- Received
- May 1, 2023
- Decided
- Jan 19, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P050051
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the migration of ARCHITECT AUSAB (Mag/Sep) from the ARCHITECT i2000SR to the ARCHITECT i1000SR system.
Source documents
Other decisions for Abbott Laboratories, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.